Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Osimertinib (AZD-9291) 是一种 EGFR 三代抑制剂,抑制二代 EGFR 抑制剂产生的 T790M 耐药突变,具有不可逆性和口服活性。Osimertinib 具有抗肿瘤活性,用于治疗 EGFR 突变的非小细胞肺癌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 198 | 现货 | ||
2 mg | ¥ 293 | 现货 | ||
5 mg | ¥ 473 | 现货 | ||
10 mg | ¥ 653 | 现货 | ||
25 mg | ¥ 987 | 现货 | ||
50 mg | ¥ 1,380 | 现货 | ||
100 mg | ¥ 1,930 | 现货 | ||
200 mg | ¥ 2,570 | 现货 | ||
500 mg | ¥ 4,730 | 现货 | ||
1 g | ¥ 6,490 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 535 | 现货 |
产品描述 | Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer. |
靶点活性 | EGFR (WT):493.8 nM, EGFR (L858R/T790M):11.44 nM, EGFR (exon 19 deletion):12.92 nM |
体外活性 |
方法:人非小细胞肺癌细胞 PC-9 (exon 19del)、H3255 (L858R)、PC-9ER (exon 19del+T790M) 和 H1975 (L858R+T790M) 用 Osimertinib (0.0001-10 µmol/L) 处理 72 h,使用 MTS 方法检测细胞生长抑制情况。 结果:Osimertinib 剂量依赖诱导 PC-9、H3255、PC-9ER 和 H1975 细胞生长,IC50 分别为 41、26、41 和 31 nM。[1] 方法:EGFR 突变的人非小细胞肺癌细胞 PC-9、H1975、H1650 和 H3255 用 Osimertinib (0.1-1000 nM) 处理 6 h,使用 Western Blot 方法检测靶点蛋白表达水平。 结果:Osimertinib 抑制 EGFR 突变肿瘤细胞的 pEGFR(Y1068)、pERK(P-p44/42)、pAKT(S473)。[2] 方法:人非小细胞肺癌细胞 NCI-H1975 用 Osimertinib (10-100 nM) 处理 24 h,然后用 2-20 Gy 的剂量照射,使用 Flow Cytometry 方法分析细胞周期情况。 结果:联合治疗组 G2/M 和 S 期细胞比例呈剂量依赖性降低。Osimertinib 减少照射后 G2/M 期细胞周期停滞。[3] |
体内活性 |
方法:为检测体内抗肿瘤活性,将 Osimertinib (5-10 mg/kg) 口服给药给携带人肺癌肿瘤 H1975、PC9 和 A431 的 SCID 小鼠,每天一次,持续七天。 结果:Osimertinib 治疗显著抑制 H1975、PC9 和 A431 肿瘤的生长,表明在体内具有抗肿瘤活性。[4] 方法:为检测体内抗肿瘤活性,将 Osimertinib (6 mg/kg) 口服给药给用 PC-9/ffluc 细胞构建软脑膜癌病 (LMC) 模型的 SHO-SCID 小鼠,每天一次,持续五十天。 结果:Osimertinib 治疗明显延缓了 LMC 的发展。第三代 EGFR-TKI Osimertinib 可能是由 EGFR 突变型肿瘤引起的第一代或第二代 EGFR-TKI 耐药性 LMC 的有效治疗方法。[5] |
激酶实验 | ACY-1215 is dissolved and subsequently diluted in assay buffer [50 mM HEPES, pH 7.4, 100 mM KCl, 0.001% Tween-20, 0.05% BSA, and 20 μM tris(2-carboxyethyl)phosphine] to 6-fold the final concentration. HDAC enzymes are diluted to 1.5-fold of the final concentration in assay buffer and pre-incubated with ACY-1215 for 10 minutes before the addition of the substrate. The amount of FTS (HDAC1, HDAC2, HDAC3, and HDAC6) or MAZ-1675 (HDAC4, HDAC5, HDAC7, HDAC8, and HDAC9) used for each enzyme is equal to the Michaelis constant (Km), as determined by a titration curve. FTS or MAZ-1675 is diluted in assay buffer to 6-fold the final concentration with 0.3 μM sequencing grade trypsin. The substrate/trypsin mix is added to the enzyme/compound mix and the plate is shaken for 60 seconds and then placed into a SpectraMax M5 microtiter plate reader. The enzymatic reaction is monitored for release of 7-amino-4-methoxy-coumarin over 30 minutes, after deacetylation of the lysine side chain in the peptide substrate, and the linear rate of the reaction is calculated[1]. |
细胞实验 | AZD-9291 is dissolved in DMSO and stored, and then diluted with appropriate medium before use[1]. PC-9 cells are seeded into T75 flasks (5×105 cells/flask) in RPMI growth media and incubated at 37°C, 5% CO2. The following day the media is replaced with media supplemented with a concentration of EGFR inhibitor equal to the EC50 concentration predetermined in PC-9 cells. Media changes are carried out every 2-3 days and resistant clones allowed to grow to 80% confluency prior to the cells being trypsinised and reseeded at the original seeding density in media containing twice the concentration of EGFR inhibitor. Dose escalations are continued until a final concentration of 1.5 μM Gefitinib, 1.5 μM Afatinib, 1.5 μM WZ4002 or 160 nM AZD-9291 are achieved[1]. |
别名 | AZD-9291, Mereletinib, 奥希替尼 |
化合物与蛋白结合的复合物 |
Crystal Structure of EGFR(L858R/T790M/C797S) in complex with Osimertinib |
分子量 | 499.61 |
分子式 | C28H33N7O2 |
CAS No. | 1421373-65-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 22 mg/mL(44 mM)
DMSO: 92 mg/mL (184.1 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.0016 mL | 10.0078 mL | 20.0156 mL | 50.039 mL |
5 mM | 0.4003 mL | 2.0016 mL | 4.0031 mL | 10.0078 mL | |
10 mM | 0.2002 mL | 1.0008 mL | 2.0016 mL | 5.0039 mL | |
20 mM | 0.1001 mL | 0.5004 mL | 1.0008 mL | 2.502 mL | |
DMSO | 50 mM | 0.04 mL | 0.2002 mL | 0.4003 mL | 1.0008 mL |
100 mM | 0.02 mL | 0.1001 mL | 0.2002 mL | 0.5004 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Osimertinib 1421373-65-0 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR AZD-9291 AZD 9291 Inhibitor Ba/F3 cells H1975 PC-9 tumor xenograft model ErbB-1 AZD9291 HER1 inhibit cancer Mereletinib 奥希替尼 Epidermal growth factor receptor inhibitor